Structural topology defines protective CD8+ T cell epitopes in the HIV proteome - PubMed (original) (raw)
. 2019 May 3;364(6439):480-484.
doi: 10.1126/science.aav5095.
Elizabeth J Rossin # 3 4, Jonathan Urbach 1, Christian Landeros 1, David R Collins 1 5, Chioma Nwonu 1, Itai Muzhingi 1, Melis N Anahtar 1 6, Olivia M Waring 1 7, Alicja Piechocka-Trocha 1 5, Michael Waring 1 5, Daniel P Worrall 1, Musie S Ghebremichael 1, Ruchi M Newman 1, Karen A Power 1, Todd M Allen 1, James Chodosh 4, Bruce D Walker 8 3 5 7
Affiliations
- PMID: 31048489
- PMCID: PMC6855781
- DOI: 10.1126/science.aav5095
Structural topology defines protective CD8+ T cell epitopes in the HIV proteome
Gaurav D Gaiha et al. Science. 2019.
Abstract
Mutationally constrained epitopes of variable pathogens represent promising targets for vaccine design but are not reliably identified by sequence conservation. In this study, we employed structure-based network analysis, which applies network theory to HIV protein structure data to quantitate the topological importance of individual amino acid residues. Mutation of residues at important network positions disproportionately impaired viral replication and occurred with high frequency in epitopes presented by protective human leukocyte antigen (HLA) class I alleles. Moreover, CD8+ T cell targeting of highly networked epitopes distinguished individuals who naturally control HIV, even in the absence of protective HLA alleles. This approach thereby provides a mechanistic basis for immune control and a means to identify CD8+ T cell epitopes of topological importance for rational immunogen design, including a T cell-based HIV vaccine.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Conflict of interest statement
Competing interests: G.D.G., E.J.R., and B.D.W. have filed a provisional patent application (62/817,094).
Figures
Fig. 1.. Structure-based network analysis identifies amino acid residues with low mutational tolerance.
(A) Scatter plot of average mutational tolerance and network score for TEM-1 b-lactamase residues (red, active site residues Ser70, Lys73, Glu166, and Asn170). (B) Comparative receiver operator curves (ROC) and area under the curve (AUC) characteristics for network score, RSA, and sequence entropy to identify the bottom 10% of residues of low mutational tolerance in TEM-1 b-lactamase. (C) Structure-based network schematic for Gag p24 monomer (PDB ID: 3J34, chain C), including amino acid residues (nodes) and noncovalent interactions (edges). Edge width indicates interaction strength and node size indicates relative network score. (D and E) Comparison of Gag p24 and HIV proteome network scores (binned by quintile: low, 2nd, 3rd, 4th, and high; top 5% in gray) with viral sequence entropy. (F) Comparison of viral infectivity of TZM-bl cells and (G and H) viral spreading within GXR cells after mutation of conserved, highly networked residues (blue); conserved, poorly networked residues (red); and nonconserved, poorly networked residues (green). Statistical analyses by one-way analysis of variance and Wilcoxon matched pairs test. (I and J) Scatter plot of sequence conservation and network scores with mutant virus infectivity. Correlations were calculated by Spearman’s rank correlation coefficient. Statistical comparisons were made using Mann-Whitney U test. For comparisons of more than two groups, Kruskal-Wallis test with Dunn’s post hoc analyses was used. Calculated P values are as follows: NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Fig. 2.. Network score distinguishes HIV proteins and CTL epitopes associated with protective, neutral, and risk-associated HLA alleles.
(A) Ranked median second-order degree centrality values (red dots) for HIV proteins (median, interquartile range). (B and C) Network scores for risk and protective allele epitopes _B*35Px_-DL9 and _B*57_-KF11 (HLA anchor residues, red; TCR contact residues, blue). Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. (D) Network-based depiction of _B*35Px_-DL9 in open gp120 (left, red) (PDB ID: 3J70, chain D) and _B*57_-KF11 in monomeric Gag p24 (right, blue) (PDB ID: 3J34, chain C). (E) Ranked median epitope network scores for individual HLA alleles (median, interquartile range). GWAS-defined protective and risk HLA alleles indicated in blue and red, respectively. (F) Comparison of epitope network scores presented by protective, neutral, and risk HLA alleles. (G) Comparison of epitope network scores of immunodominant epitopes presented by HLA alleles associated with protection (blue; _B*5701_-TW10, _B*5201_-RI8, _B*2705_-KK10, _B*1402_-DA9) and risk (red; _B*0801_-FL8, _B*3501_-DL9, _B*0702_-RV9, _Cw*07_-RY11). (H) Scatter plot of GWAS-defined protective HLA allele odds ratios (OR) to median epitope network score. (I) Ranked network scores of each amino acid type across the HIV proteome (median, interquartile range). HLA-B*57 anchor residues denoted in blue. Statistical comparisons were made using Mann-Whitney U test. For comparisons of more than two groups, Kruskal-Wallis test with Dunn’s post hoc analyses was used. Correlations were calculated by Spearman’s rank correlation coefficient. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Fig. 3.. Targeting of topologically important epitopes distinguishes HIV controllers from progressors irrespective of HLA allele.
(A and B) Proliferative CTL responses in a single representative controller (top) and progressor (bottom) after 6-day incubation of carboxyfluorescein succinimidyl ester (CFSE)–loaded peripheral blood mononuclear cells with optimal epitopes matched to the person’s HLA haplotype. VL, viral load. (C) Residue network scores of epitopes targeted in (B) (red, HLA anchor; blue, TCR contact). (D) Network-based depiction of _A*02_-KL9 and _B*07_-RI10 in open (top; PDB ID: 3J70, chain D) and closed (bottom; PDB ID: 5T3X) gp120 trimeric conformations. A single subunit of trimeric, open gp120 is presented for ease of epitope visualization. (E) Proliferative responses of controllers (blue), intermediates (green), and progressors (red). The x axis depicts all CTL epitopes ranked by epitope network score from lowest to highest. (F to H) Comparison of controllers (C; n = 46 individuals), intermediates (I; n = 25), and progressors (P; n = 43) by summed epitope network scores, summed proliferative responses, and summed epitope network scores scaled by proliferative CTL response. (I and J) Comparison of controllers with nonprotective alleles (NPC; n = 18) and protective alleles (PC; n = 28) by summed epitope network scores (I) and summed epitope network scores scaled by magnitude of proliferative CTL response (J). (K) Comparison of B*57+ controllers (C; n = 17) and B*57+ progressors (P; n = 7) by summed epitope network scores scaled by magnitude of CTL proliferation. (L) CFSE dilution of immunodominant CTL responses from a single representative B*57 + controller and B*57+ progressor. (M) Residue network scores of CTL epitopes targeted in (L). (N and O) Comparison of controllers (C; n = 14) and progressors (P; n = 14) with similar magnitude of summed CTL proliferation (upper) by CTL proliferation (N) and epitope network scores (O). Statistical comparisons were made using Mann-Whitney U test. For comparisons of more than two groups, Kruskal-Wallis test with Dunn’s post hoc analyses was used. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Fig. 4.. Topologically important CTL epitopes targeted by HIV controllers are infrequently mutated in vivo.
(A and D) CFSE dilution of immunodominant CTL responses from a single representative controller and progressor. (B and E) Network scores of the _B*53_-YF9 and _B*08_-FL8 epitopes (red, HLA anchor; blue, TCR contact). (C and F) WebLogo of _B*53_-YF9 and _B*08_-FL8 sequence data (red, HLA anchor; blue, TCR contact; green, flanking). (G) Network representation of the _B*08_-FL8 and _B*53_-YF9 epitopes within the Nef dimer (PDB ID: 2XI1). (H) Comparison of average number of mutations within epitopes targeted by controllers (n = 9) and progressors (n = 15) for each individual patient. (I) Comparison of the percent frequency of mutations at HLA anchor (blue), TCR contact (red), and flanking residues (black) between controller-targeted (open bars) and progressor-targeted epitopes (filled bars). Statistical comparisons were made using Mann-Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Comment in
- Topological perspective on HIV escape.
McMichael AJ, Carrington M. McMichael AJ, et al. Science. 2019 May 3;364(6439):438-439. doi: 10.1126/science.aax4989. Science. 2019. PMID: 31048479 Free PMC article. No abstract available.
Similar articles
- Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes.
Murakoshi H, Akahoshi T, Koyanagi M, Chikata T, Naruto T, Maruyama R, Tamura Y, Ishizuka N, Gatanaga H, Oka S, Takiguchi M. Murakoshi H, et al. J Virol. 2015 May;89(10):5330-9. doi: 10.1128/JVI.00020-15. Epub 2015 Mar 4. J Virol. 2015. PMID: 25741000 Free PMC article. - Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
Ojwach DBA, MacMillan D, Reddy T, Novitsky V, Brumme ZL, Brockman MA, Ndung'u T, Mann JK. Ojwach DBA, et al. J Virol. 2018 Sep 12;92(19):e00811-18. doi: 10.1128/JVI.00811-18. Print 2018 Oct 1. J Virol. 2018. PMID: 29997209 Free PMC article. - Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.
Borthwick N, Lin Z, Akahoshi T, Llano A, Silva-Arrieta S, Ahmed T, Dorrell L, Brander C, Murakoshi H, Takiguchi M, Hanke T. Borthwick N, et al. PLoS One. 2017 Apr 27;12(4):e0176418. doi: 10.1371/journal.pone.0176418. eCollection 2017. PLoS One. 2017. PMID: 28448594 Free PMC article. Clinical Trial. - Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
Ferrari G, Kostyu DD, Cox J, Dawson DV, Flores J, Weinhold KJ, Osmanov S. Ferrari G, et al. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1433-43. doi: 10.1089/08892220050140982. AIDS Res Hum Retroviruses. 2000. PMID: 11018863 Review. - Therapeutic Vaccine Against HIV, Viral Variability, Cytotoxic T Lymphocyte Epitopes, and Genetics of Patients.
Fleury H, Tumiotto C, Bellecave P, Recordon-Pinson P. Fleury H, et al. AIDS Res Hum Retroviruses. 2018 Jan;34(1):27-30. doi: 10.1089/aid.2017.0175. Epub 2017 Oct 12. AIDS Res Hum Retroviruses. 2018. PMID: 28899104 Review.
Cited by
- Modelling HIV-1 control and remission.
Vemparala B, Chowdhury S, Guedj J, Dixit NM. Vemparala B, et al. NPJ Syst Biol Appl. 2024 Aug 8;10(1):84. doi: 10.1038/s41540-024-00407-8. NPJ Syst Biol Appl. 2024. PMID: 39117718 Free PMC article. Review. - Structure-based network analysis predicts pathogenic variants in human proteins associated with inherited retinal disease.
Hauser BM, Luo Y, Nathan A, Al-Moujahed A, Vavvas DG, Comander J, Pierce EA, Place EM, Bujakowska KM, Gaiha GD, Rossin EJ. Hauser BM, et al. NPJ Genom Med. 2024 May 27;9(1):31. doi: 10.1038/s41525-024-00416-w. NPJ Genom Med. 2024. PMID: 38802398 Free PMC article. - Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules.
Tano-Menka R, Singh NK, Muzhingi I, Li X, Mandanas MV, Kaseke C, Crain CR, Zhang A, Ogunshola FJ, Vecchiarello L, Piechocka-Trocha A, Bashirova A, Birnbaum ME, Carrington M, Walker BD, Gaiha GD. Tano-Menka R, et al. Structure. 2024 Aug 8;32(8):1121-1136.e5. doi: 10.1016/j.str.2024.04.015. Epub 2024 May 10. Structure. 2024. PMID: 38733995 Free PMC article. - Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?
Harper J, Betts MR, Lichterfeld M, Müller-Trutwin M, Margolis D, Bar KJ, Li JZ, McCune JM, Lewin SR, Kulpa D, Diallo DD, Lederman MM, Paiardini M. Harper J, et al. Pathog Immun. 2024 Mar 1;8(2):115-157. doi: 10.20411/pai.v8i2.665. eCollection 2023. Pathog Immun. 2024. PMID: 38455668 Free PMC article. - Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure.
Armani-Tourret M, Bone B, Tan TS, Sun W, Bellefroid M, Struyve T, Louella M, Yu XG, Lichterfeld M. Armani-Tourret M, et al. Nat Rev Microbiol. 2024 Jun;22(6):328-344. doi: 10.1038/s41579-024-01010-8. Epub 2024 Feb 9. Nat Rev Microbiol. 2024. PMID: 38337034 Review.
References
- Walker BD, in The Vaccine Book, Bloom BR, Lambert P-H, Eds. (Academic Press, ed. 2, 2016), pp. 401–422.
- Deeks SG, Walker BD, Immunity 27, 406–416 (2007). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UM1 AI100663/AI/NIAID NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- U19 AI067854/AI/NIAID NIH HHS/United States
- P01 AI104715/AI/NIAID NIH HHS/United States
- P30 AI060354/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials